Portal de Periódicos da CAPES

Acute and long‐term pulmonary effects of platelet‐activating factor

1989; Wiley; Volume: 19; Issue: 2 Linguagem: Inglês

10.1111/j.1365-2222.1989.tb02356.x

1365-2222

Jean Michel Mencia‐Huerta, David Hosford, P. Braquet,

Food Allergy and Anaphylaxis Research

Clinical & Experimental AllergyVolume 19, Issue 2 p. 125-142 Acute and long-term pulmonary effects of platelet-activating factor J. M. MENCIA-HUERTA, Corresponding Author J. M. MENCIA-HUERTA Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, FranceJean Michel Mencia-Huerta, Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, France.Search for more papers by this authorD. HOSFORD, D. HOSFORD Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, FranceSearch for more papers by this authorP. BRAQUET, P. BRAQUET Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, FranceSearch for more papers by this author J. M. MENCIA-HUERTA, Corresponding Author J. M. MENCIA-HUERTA Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, FranceJean Michel Mencia-Huerta, Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, France.Search for more papers by this authorD. HOSFORD, D. HOSFORD Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, FranceSearch for more papers by this authorP. BRAQUET, P. BRAQUET Institut Henri Beaufour, 1 avenue des Tropiques, 91952 Les Ulis, FranceSearch for more papers by this author First published: March 1989 https://doi.org/10.1111/j.1365-2222.1989.tb02356.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-o-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl-choline as the active component (a new class of lipid chemical mediators). J Bid Chem 1979; 254: 93355– 8. 2 Benveniste J, Tencé M, Varenne P, Bidault J, Boullet C, Polonsky J. Semi-synthesis and proposed structure of platelet-activating factor (PAF): PAF-acether an alkyl ether analog of lysophosphatidyl-choline. CR Acad Sci 1979; 289D: 1037– 40. 3 Polonsky J, Tencé M, Varenne P, Das BP, Lunel J, Benveniste J. Release of 1-O-alkyl-glyceryl-3-phosphoryl-choline. o-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci USA 1980; 77: 7019– 23. 4 Mencia-Huerta JM, Ninio E, Roubin R, Benveniste J. Is platelet-activating factor (PAF-acether) synthesis by murine peritoneal macrophage a two step process Agents Actions 1981; 11: 556– 8. 5 Vargaftig BB. Carrageenan and thrombin trigger prostaglandin synthetase-independent aggregation of rabbit platelets: inhibition by phospholipase A2 inhibitors. J Pharm Pharmacol 1977; 29: 222– 8. 6 Wykle RL, Malone B, Snyder F. Enzymatic synthetic of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem 1980; 255: 10256– 60. 7 Ninio E, Mencia-Huerta JM, Heymans F, Benveniste J. Biosynthesis of platelet-activating factor. I. Evidence for an acetyl-transferase activity in murine macrophages. Biochim Biophys Acta 1982; 710: 23– 31. 8 Alonso F, Gil MG, Sanchez-Crespo M, Mato JM. Activation of 1-alkyl-2-lyso-glycero-3-phoshocholine. Acetyl-CoA transferase during phagocytosis in human polymorphonuclear leukocytes. J Biol Chem 1982; 257: 3376– 8. 9 Ninio E, Mencia-Huerta JM, Benveniste J. Biosynthesis of platelet-activating factor (PAF-acether): Enhancement of acetyltransferase activity in murine peritoneal cells by the calcium ionophore A 23187. Biochim Biophys Acta 1983; 751: 298– 304. 10 Lenihan DJ, Lee TC. Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine: acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. Biochem Biophys Res Commun 1984; 120: 834– 9. 11 Ninio E, Joly F, Hieblot C, Bessou G, Mencia-Huerta JM, Benveniste J. Role for phosphorylation-dependent activation of acetyltransferase in the biosynthesis of PAF-acether in antigen-stimulated mouse mast cells. J Immunol 1987; 139: 154– 60. 12 White JR, Pluznik D, Ishizaka K, Ishizaka T. Antigen-induced increase in protein-kinase C activity in plasma membrane of mast cells. Proc Natl Acad Sci USA 1985; 82: 8193– 7. 13 Murphy RC, Clay KL. Chemical synthesis and mass spectrometry of PAF. In: F Snyder, ed. PAF and related lipid mediators. New York : Plenum Press, 1987: 9– 31. 14 Oda M, Satouchi K, Yasunage K, Saito J. Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A 23187. J Immunol 1985; 135: 1090– 3. 15 Keith CL, Murphy RC, Andres JL, Lynch J, Henson PM. Structure elucidation of platelet-activating factor derived from human neutrophils. Biochem Biophys Res Commun 1984, 121: 815– 25. 16 Mueller HW, O'Flaherty JT, Wykle RL. The molecular species distribution of platelet-activating factor synthesized by rabbit and human neutrophils. J Biol Chem 1984; 259: 14554– 9. 17 Weintraub ST, Ludwig JC, Mott GE, McManus LM, Lear C, Pinckard RN. Fast atom bombardment-mass spectrometric identification of molecular species of platelet-activating factor produced by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1985; 129: 868– 76. 18 Ramesha CS, Pickett WC. Species-specific variations in the molecular heterogeneity of the platelet-activating factor. J Immunol 1987; 138: 1559– 63. 19 Sugiura T, Waky K. Composition of alkyl ether-linked phospholipids in mammalian tissues. In: F Snyder, ed. PAF and related lipid mediators. New York : Plenum Press, 1987: 55– 85. 20 Sturk A, ten Cate JW, Hosford D, Mencia-Huerta JM, Braquet P. Synthesis, catabolism and pathophysiological role of platelet-activating factor. In: R Paoletti, ed. Advances in inflammation research, New York : Raven Press, 1989, in press. 21 Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research, Pharmacol Rev 1987; 39: 97– 145. 22 Godfroid JJ, Braquet P. PAF-acether specific binding sites:1. Quantitative SAR study of PAF-acether isosteres. Trends Pharmacol Sci 1986; 7: 368– 73. 23 Braquet P, Godfroid JJ. PAF-acether specific binding sites:2. Design of specific antagonists. Trends Pharmacol Sci 1986; 7: 397– 403. 24 Braquet P, Chabrier PE, Mencia-Huerta JM. The promise of platelet-activating factor antagonists. ISI Atlas of Sciences, 1988; 12: 135– 57. 25 Snyder F. Enzymatic pathways for platelet-activating factor, related alkyl glycerolipids and their precursors. In: F Snyder, ed. PAF and related lipid mediators. New York : Plenum Press. 1987: 89– 113. 26 Barbaro JF, Zvaifer NJ. Antigen-induced histamine release from platelets of rabbits producing homologous PCA antibody. Proc Soc Exp Biol Med 1966; 122: 1245– 7. 27 Siraganian RP, Osler AG. Antigenic release of histamine from rabbit leukocytes. J Immunol 1970; 106: 1244– 9. 28 Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: The role for IgE, basophils and a platelet-activating factor. J Exp Med 1972; 136: 1356– 77. 29 Lewis RA, Goetzl, EJ, Vasserman S, Valone FH, Rubin RH, Austen KF. The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol 1975; 114: 87– 92. 30 Clark RAF, Gallin JI, Kaplan AP. Mediator release from basophil granulocytes in chronic myelogenous leukemia. J Allergy Clin Immunol 1976; 58: 623– 34. 31 Benveniste J, Camussi G, Mencia-Huerta JM. Cellular origin of platelet-activating factor (PAF). Fed Proc 1977; 36: 1329(abstr). 32 Mencia-Huerta JM, Benveniste J. Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol 1979; 9: 409– 15. 33 Denburg JA, Williams DB, Kinlough-Rathbone RL, Cazenave JP, Bienenstock J. Platelet-activating factor: regulation by mast cells and aspirin. Agents Actions 1984; 14: 300– 5. 34 Dy M, Lebel B, Kamoun P, Hamburger J. Histamine production during the anti-allograft response: Demonstration of a new lymphokine enhancing histamine synthesis. J Exp Med 1981; 153: 293– 309. 35 Razin E, Cordon-Cardo C, Good RA. Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci USA 1981; 78: 2559– 61. 36 Tertian G, Yung YP, Guy-Grand D, Moore MAS. Long-term culture of murine mast cells: description of a growth factor-dependent culture technique. J Immunol 1981; 127: 788– 94. 37 Schrader JW, Lewis SJ, Clark-Lewis I, Culvenor JG. The persisting (P) cell: histamine content, regulation by T cell-derived factor, origin from a bone marrow precursor and relationship to mast cells. Proc Natl Acad Sci USA 1981; 78: 323– 7. 38 Nagao K, Yokoro K, Aronson SA. Continuous lines of basophils/mast cells derived from normal bone marrow. Science 1981; 212: 333– 5. 39 Razin E, Stevens RL, Akiyama F, Schmid K, Austen KF. Culture from mouse bone marrow of a sub-class of mast cells possessing distinct chondroitin sulfate proteoglycans with glycosaminoglycans rich in N-acetylgalaetosamine-4,6-disulfate. J Biol Chem 1982; 257: 7229– 36. 40 Razin E, Mencia-Huerta JM, Stevens RL, Lewis RA, Liu FT, Corey EJ, Austen KF. IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan. β-hexosaminidase and histamine from cultured bone marrow-derived mouse mast cells. J Exp Med 1983; 157: 189– 201. 41 Razin E, Mencia-Huerta JM, Lewis RA, Corey EJ, Austen KF. Generation of leukotriene C4 from a subclass of mast cells differenciated in vitro from mouse bone marrow. Proc Natl Acad Sci USA 1982; 79: 465– 7. 42 Mencia-Huerta JM, Razin E, Ringel EW, Corey EJ, Hoover D, Austen KF. Immunologic- and ionophore-induced release of leukotriene B4 from mouse bone marrow-derived mast cells. J Immunol 1983; 130: 1885– 90. 43 Wong GHW, Clarck-Lewis I, McKimm-Breschkin JL, Schrader JW. Interferon-gamma-like molecule induces Ia antigens on cultured mast cell progenitors. Proc Natl Acad Sci USA 1982; 79: 6989– 93. 44 Mencia-Huerta JM, Ninio E. Biosynthesis and release of PAF-acether by mouse bone marrow-derived mast cells. In: F Snyder, ed. Platelet-activating factor and related lipid mediators. New York : Plenum Press, 1987: 425– 45. 45 Mencia-Huerta JM, Benhamou M. PAF-acether: an update. In: AB Kay, ed. Asthma, clinical pharmacology and therapeutic progress. Oxford : Blackwell Scientific, 1986: 237– 51. 46 Mencia-Huerta JM, Lewis RA, Razin E, Austen KF. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. J Immunol 1983; 131: 2958– 64. 47 Benhamou M, Ninio E, Salem P, Hieblot C, Bessou G, Pitton C, Liu FT, Mencia-Huerta JM. Decrease in IgE Fc receptor expression on mouse bone marrow-derived mast cells and inhibition of PAF-acether formation and β-hexosaminidase by dexamethasone. J Immunol 1986; 136: 1385– 90. 48 Razin E, Ihle JN, Seldin D, Mencia-Huerta JM, Katz HR, Leblanc PA, Hein A, Caulifield JP, Austen KF, Stevens RL. Interleukin 3: a differentiation and growth factor for the mouse mast cells that contain chondroitin sulfate E proteoglycan. J Immunol 1984; 132: 1479– 86. 49 Lynch JM, Lotner GZ, Betz SJ, Henson PM. The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol 1979; 123: 1219– 26. 50 Kay AB. Mediators and inflammatory cells in asthma. In: AB Kay, ed. Asthma, clinical pharmacology and therapeutic progress. Oxford : Blackwell Scientific, 1986: 1– 10. 51 Jouvin-Marche E, Grzych JM, Boulet C, Capron M, Benveniste J. Formation of PAF-acether by human eosinophils. Fed Proc 1984; 43: 1924(abstr). 52 Lee TC, Lenihan DJ, Malone B, Roddy LL, Wasseman SI. Increased biosynthesis of platelet-activating factor in activated eosinophils. J Biol Chem 1984; 259: 5526– 30. 53 Frigas F, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986; 77: 527– 37. 54 Chignard M, Le Couedic JP, Tencé M, Vargaftig BB, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979; 275: 799– 800. 55 Chignard M, Le Couedic JP, Delautier D, Benveniste J. Formation of PAF-acether and of another aggregating phospholipids by human platelets. Fed Proc 1983; 42: 659(abstr). 56 Chignard M, Le Couedic JP, Vargaftig BB, Benveniste J. Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol 1980; 46: 455– 64. 57 Bourgain RH, Andries R, Bourgain C, Braquet P, Vargaftig BB. PAF-acether antagonists block platelet and leukocyte recruitment in electric shock-induced arterial thrombosis. Proceedings of the satellite meeting on Recent advances in platelet-activating factor. Brisbane , 1987: 47 (abstr). 58 Alam I, Silver J. Acetyltransferase activity in human platelet microsomes and washed platelets. Biochim Biophys Acta 1986; 884: 67– 72. 59 Mencia-Huerta JM, Benvensite J. Platelet-activating factor (PAF-acether) and macrophages. II: Phagocytosis-associated release of PAF-acether from rat peritoneal macrophages. Cell Immunol 1981; 57: 281– 92. 60 Czop J, Fearon DT, Austen KF. Opsonin-independent phagocytosis of activator of the alternative complement pathway by human monocytes. J Immunol 1978; 120: 1132– 40. 61 Rouzer CA, Scott WA, Kempe J, Cohen ZA. Prostaglandin synthesis by macrophages requires a specific receptor-ligand interaction. Proc Natl Acad Sci USA 1980; 77: 4279– 82. 62 Roubin R, Tencé M, Mencia-Huerta JM, Arnoux B, Benveniste J. A chemically defined monokine: macrophage-derived platelet-activating factor (PAF-acether). In: E Pick, ed. Lymphokines, Vol 8. New York : Academic Press, 1983: 249– 76. 63 Haye-Legrand I, Dulioust A, Vivier E, Roubin R, Benveniste J. Production of PAF-acether and leukotrienes by cultured mouse macrophages. Pharmacol Res Commun 1986; 18: 239– 42. 64 Arnoux B, Duval D, Benveniste J. Release of platelet-activating factors (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest 1980; 10: 437– 41. 65 Arnoux B, Caeiro MH, Landes A, Mathieu M, Duroux P, Benveniste J. Alveolar macrophages from asthmatic patients release platelet-activating factor (PAF-acether) and lyso-PAF-acether when stimulated with the specific allergen. Am Rev Respir Dis. 1982; 125: 70(abstr). 66 Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet-activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986; ii: 189– 92. 67 Mazzoni L, Morley J, Page CP, Sanjar S. Induction of hyperreactivity by platelet-activating factor in the guinea-pig. J Physiol 1985; 365: 107P. 68 Arnoux B, Jouvin-Marche E, Arnoux A, Benveniste J. Release of PAF-acether from human blood monocytes. Agents Actions 1982; 12: 713– 16. 69 Fitzgerald MF, Moncada S, Parente L. The anaphylatic release of platelet-activating factor from perfused guinea-pig lungs. Br J Pharmacol 1986; 88: 149– 53. 70 Parente L, Fitzgerald MF, Moncada S. Anaphylatic release of platelet-activating factor and eicosanoids from guinea-pigs sensitized to ovalbumine aerosol. In: B Samuelsson, R Paoletti, P Ramwell, eds. Advances in prostaglandins, thromboxane and leukotriene research, Vol. 17. New York : Raven Press, 1987: 171– 6. 71 Rotilio D, Lefort J, Detsouli A, Vergaftig BB. Absence de contribution du PAF-acether à la response anaphylactique pulmonaire in vitro chez le cobaye. J de Pharmacologie, 1983; 14: 1(abstr). 72 Parente L, Fitzgerald MF, Flower RJ, de Nucci G. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. Agents Actions 1985; 17: 312– 13. 73 Pinckard RN, Halonen M, Palmer JD, McManus LM, Shaw JO, Henson PM. Intravascular aggregation and pulmonary sequestration of platelets during IgE-induced systemic anaphylaxis in the rabbit: abrogation of lethal anaphylactic shock by platelet depletion. J Immunol 1977; 119: 2185– 93. 74 Halonen M, Lohman IC, Dunn AM, McManus LM, Palmer JD. Participation of platelets in the physiologic alterations of the AGEPC response and of IgE anaphylaxis in the rabbit. Am Rev Respir Dis 1985; 131: 11– 17. 75 Halonen M, Palmer JD, Lohman IC, McManus LM, Pinckard RN. Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis 1980; 122: 915– 24. 76 Halonen M, Palmer JD, Lohman IC, McManus LM, Pinckard RN. Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit. Am Rev Respir Dis 1981; 124: 416– 21. 77 Vargaftig BB, Lefort J, Chignard M, Benvensiste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1980; 65: 185– 92. 78 Vargaftig BB, Lefort J, Wal F, Chignard M. Role of the metabolites of arachidonate in platelet-dependent and independent experimental bronchoconstriction. Bull Eur Physiopathol Respir 1981; 17: 723– 36. 79 Chignard M, Wal F, Lefort I, Vergaftig BB. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. Eur J Pharmacol 1982; 78: 71– 9. 80 Vargaftig BB, Lefort J, Wal F, Chignard M, Medeiros MC. Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of platelet-activating factor (PAF-acether). Eur J Pharmacol 1982; 82: 121– 30. 81 Garcez Do Carmo L, Cordeiro R, Lagente V, Lefort J, Randon J, Vargaftig BB. Failure of a combined anti-histamine and anti-leukotriene treatment to suppress passive anaphylaxis in the guinea-pig. Int J Immunopharmacol 1986; 8: 985– 95. 82 Lefort J, Rotilio D, Vargaftig BB. The platelet-independent release of thromboxane A2 by PAF-acether from guinea-pigs involves mechanisms distinct from those from leukotriene. Br J Pharmacol 1984; 82: 565– 75. 83 Maridonneau-Parini I, Lagente V, Lefort J, Randon J, Russo-Marie F, Vargaftig BB. Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea-pig. Biochem Biophys Res Commun 1985; 131: 42– 9. 84 Lefort J, Malanchère E, Pretolani M, Vargaftig BB. Immunization induces bronchial hyperreactivity and increased mediator release from guinea-pig lungs. Br J Pharmacol 1986; 89: 768P. 85 Pretolani M, Lefort J, Dumarey C, Vargaftig BB. Role of lipoxygenase metabolites for the hyperesponsiveness to PAF-acether of lungs from actively sensitized guinea-pigs. J Pharmacol Exp Thr 1989, in press. 86 Detsouli A, Lefort J, Vargaftig BB. Histamine and leukotriene-independent guinea-pig anaphylactic shock unaccounted for by PAF-acether. Br J Pharmacol 1985; 84: 801– 10. 87 Lagente V, Touvay C, Randon J, Desquant S, Cirino M, Vilain B, Lefort J, Braquet P, Vargaftig BB. Interference of the PAF-acether antagonist BN 52021 with passive anaphylaxis in the guinea-pig. Prostaglandins 1987; 33: 265– 74. 88 Pretolani M, Lefort J, Malenchère E, Vargaftig BB. Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs. Eur J Pharmacol 1987; 140311– 21. 89 Lagente V, Desquand S, Hadvary F, Cirino M, Lellouch-Tubiana A, Vargaftig BB. Interference of the PAF antagonist Ro 19–3704 with PAF- and antigen-induced bronchoconstriction in the guinea-pig. Br J Pharmacol 1988; 94: 27– 36. 90 Desquand S, Touvay C, Randon J, Lagente V, Maridonneau-Parini I, Lefort J, Etienne A, Braquet P, Vargaftig BB. Interference of Ginkolide B (BN 52021) with the broncho-pulmonary effects of PAF-acether in the guinea-pig. Eur J Pharmacol 1986; 127: 83– 95. 91 Braquet P. Involvement of PAF-acether in various immune disorders using BN 52021 (Gingkolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L. In: B Samuelsson, R Paoletti, PW Ramwell, eds. Advances in prostaglandin, thromboxane and leukotriene research, Vol. 16. New York : Raven Press, 1986: 179– 98. 92 Braquet P, Etienne A, Touvay C, Bourgain RH, Lefort J, Vargaftig BB. Involvement of platelet-activating factor in respiratory anaphylaxis demonstrated by PAF-acether inhibitor, BN 52021. Lancet 1986; i: 1501– 2. 93 Casals-Stenzel J, Muacevic G, Heuer H. Modulation of the endotoxin shock and anaphylactic lung reaction by WEB 2086, a new potent antagonist of PAF. In: TN Gatlinburg, ed. Second international conference on platelet-activating factor and structurally related alkyl ether lipids. 1986: 108(abstr). 94 Braquet P. The ginkgolides: potent platelet-activating factor antagonists isolated from Ginkgo biloba L.: chemistry, pharmacology and clinical applications. Drugs of the Future 1987; 12: 643– 99. 95 Pretolani M, Page CP, Lefort J, Lagente V, Vargaftig BB. Parmacolocical modulation of the respiratory and haematological changes accompanying active anaphylaxis in the guinea-pig. Eur J Pharmacol 1986; 125: 403– 9. 96 Berti F, Omini C, Rossoni G, Braquet P. Protection by two ginkgolides, BN 52020 and BN 52021, against guinea-pig lung anaphylaxis. Pharmacol Res Commun 1986; 18: 775– 93. 97 Berti F, Galli G, Magni F, Rossoni G, Villa L. The ginkgolide BN 52021 protects guinea-pigs from lung and heart anaphylaxis. In: P Braquet, ed. The role of platelet-activating fetor in immune disorders. New trends in lipid mediator research, Vol. 2, Karger, Basel 1988: 128– 44. 98 Guinot P, Brambilla C, Duchier J, Braquet P, Bonvoisin B, Cournot A. Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergen in asthmatic patients: a preliminary study. Prostaglandins 1987; 34: 723– 31. 99 Gateau O. Acute pulmonary and cardiovascular effects of platelet-activating factor in man: Relevance in anaphylactic shock. Prostaglandins 1987; 34: 182(abstr). 100 Braquet P, Paubert-Braquet M, Vargaftig BB. Platelet-activating factor, a potential mediator of shock. In: B Samuelsson, R Paoletti, P Ramwell eds. Advances in prostaglandin, thromboxane and leukotriene research, Vol. 17. New York : Raven Press, 1987: 818– 23. 101 Wardlaw AJ, Kay AB. PAF-acether is a potent chemotactic factor for human eosinophils. J Allergy Clin Immunol 1986; 77: 236– 42. 102 Lellouch-Tubiana A, Lefort J, Simon MT, Pfister A, Vargaftig BB. Eosinophil recruitment into guinea-pig lungs after PAF-acether and allergen administration; modulation by prostayclin, platelet depletion and selective antagonists. Am Rev Respir Dis 1988; 137: 948– 54. 103 Vargaftig BB, Braquet P. PAF-acether to day: relevance for acute experimental anaphylaxis. Br Med Bull 1987; 43: 312– 35. 104 Henocq E, Vargaftig BB. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet 1986; i: 1378– 9. 105 Bruinjzeel PLM, Koenderman L, Kok PTM, Hamelin ML, Verhagne JL. Platelet-activating factor (PAF-acether) induced release of leukotriene C4 formation and luminol-dependent chemiluminescence by human eosinophils. Pharmacol Res Commun 1986; 18: 61– 9. 106 Peterson CG, Skoog V, Venge P. Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology 1986; 171: 1– 13. 107 Lellouch-Tubiana A, Lefort J, Pirotzky E, Vargaftig BB, Pfister A. Ultrasturctural evidence for extra-vascular platelet recruitment in the lung upon intravenous injection of PAF-acether to guinea-pigs. Br J Exp Pathol 1985; 66: 345– 55. 108 Lellouch-Tubiana A, Lefort J, Pfister A, Vargaftig BB. Interaction between granulocytes and platelets with the guinea-pig lungs in passive anaphylactic shock. Correlation with PAF-acether-induced lesions. Int Arch Allergy Appl Immunol 1987; 83: 198– 205. 109 Morley J, Sanjar S, Page, CP. The platelet in asthma. Lancet 1984; ii: 1142– 4. 110 Rola-Plesczynski M. Immunoregulation by leukotrienes and other lipoxygenase metabolites. Immunol Today 1985; 6: 302– 7. 111 Goodwin JS, Ceuppens J. Immunoregulation of the immune response by prostaglandins. J Clin Immunol 1983; 3: 295– 315. 112 Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 1982; 218: 286– 8. 113 Beaubien BB, Tippins JR, Morris HR. Platelet-activating factor stimulation of peptide-leukotrience release: inhibition by vasoactive intestinal peptide. Biochem Biophys Res Commun 1984; 125: 105– 8. 114 Di Marzo V, Tippins JR Morris, HR. Neuropeptides and leukotriene release: effect of peptide histidine isoleucine and secretin in platelet-activating factor-stimulated rat lung. Neuropeptides 1987; 9: 51– 8. 115 Di Marzo V, Tippins JR, Morris HR. PAF-mediated leukotriene biosynthesis in lungs: control by the neuropeptidergic system. Prostaglandins 1987; 34: 185(abstr). 116 Rodrigue F, Hoff P, Touvay C, Villain B, Carré C, Mencia-Huerta JM, Braquet P. Platelet-activating factor induces the release of substance P and vasoactive intestinal peptide from guinea-pig lung tissues. In: P Braquet, ed. New trends in lipid mediator research, Vol. 1, Karger: Basel , 1988: 93– 8. 117 Barnes PJ. Neuropeptides in the airways: Functional significance. In: AB Kay, ed. Asthma clinical pharmacology and therapeutic progress. Oxford : Blackwell Scientific, 1986: 58– 72. 118 Barnes PJ. Neuropeptides in the lung: localization, function and pathophysiologic implications. J Allergy Clin Immunol 1987; 79: 285– 95. 119 Payan DG, McGillis JP, Goetzl EJ. Neuroimmunology. Adv Immunol 1986; 39: 299– 323. 120 Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983; 131: 1613– 15. 121 Cockcroft DW, Killian DN, Mellon JJA. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235– 43. 122 Fish JE, Rosenthal RR, Batra G. Airway responses to methacholine in allergic and non-allergic subjects. Am Rev Respir Dis 1976; 13: 579– 86. 123 Spector S, Farr R. Bronchial inhalation challenge with antigens. J Allergy Clin Immunol 1979; 64: 580– 6. 124 Gleich GJ, Frigas E, Fillay WV, Loegering DA. Eosinophils and bronchial inflammation. In: AB Kay, KF Austen, LM Lichtenstein, eds. Asthma, physiology, immunopharmacology and treatment. New York : Academic Press, 1984: 195– 207. 125 de Monchy JGR, Kaufmann UF, Venge P, Koetes GH Jansen HM, Sluites JH, de Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reaction. Am Rev Respir Dis 1985; 131: 373– 7. 126 Fukuda T, Dunnette SL, Reed CE, Ackerman SJ, Peters MS, Gleich GJ. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. Am Rev Respir Dis 1985; 132: 981– 5. 127 Touvay C, Vilain B, Pfister A, Pignol B, Mencia-Huerta JM, Braquet P. Functional and morphologic alterations of guinea-pig lung induced by chronic infusion of platelet-activating factor support a role for the mediator in bronchial hyperresponsiveness. In: P Braquet, ed. New trends in lipid mediator research, Vol. 2. Karger: Basel , 1988: 26– 31. 128 Pagel W. Zur pathologie des asthma bronchiale. Virchows Arch Path Anat Physiol 1932; 286: 580– 90. 129 Hahn HL, Hartlage J, Lang M. Effect of platelet activating factor on submucosal gland morphology—Comparison to acetylcholine. Fed Proc 1986; 45: 3085(abstr). 130 Wirtz H, Lang M, Sannwald U, Hahn H-L. Mechanism of platelet-activating factor (PAF)-induced secretion of mucus from tracheal submucosal glands in the ferret. Fed Proc 1986; 45: 418(abstr). 131 Guinot P, Braquet P, Duchier J, Cournot A. Inhibition of PAF-acether-induced weal and flare reaction in man by a specific PAF-antagonist. Prostaglandins 1986; 32: 160– 3. 132 Barnes PJ, Chung KS, Evans TW, Rogers DS. Increased airway vascular permeability induced by platelet-activating factor: effect of specific antagonism and platelet depletion. Br J Pharmacol 1986; 89: 764P. 133 Evans TW, Chung KF, Rogers DF, Barnes PJ. Effect of platelet activating factor on airway vascular permeability: possible mechanisms. J Appl Physiol 1987: 479– 84. 134 Hamasaki Y, Mojarad M, Saga T, Tai HH, Said SI. Platelet-activating factor raises airway and vascular pressures and induces edema in lung perfused with platelet-free solution. Am Rev Respir Dis 1984; 129: 742– 6. 135 Heffner JE, Shoemaker SA, Canham EM, Patel M, McMurthy IF, Morris HG, Repine JE. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. J Clin Invest 1983; 71: 351– 7. 136 Preseott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Medical Sciences 1984; 81: 3534– 8. 137 Bussolino F, Brevario F, Tetta C, Aglietta M, Mantovani A, Dejana E. Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest 1986; 77: 2027– 33. 138 Bussolino F, Camussi G, Aglietta M, Braquet P, Bosia A, Pescarmona G, Sanavio F, D'Urso N, Marchisio PC. Human endothelial cells are target for platelet-activating factor (PAF) I. PAF induces changes in cytoskeleton structures. J Immunol 1987; 139: 2439– 46. 139 Touvay C, Coyle A, Vilain B, Page CP, Braquet P. Effect of BN 52021 on antigen-induced bronchial hyperreactivity in guinea-pigs. Fed Proc 1987; 46: 5155(abstr). 140 Beijer L, Botting J, Crook P, Ovekan AD, Page CP, Rylander R. The involvement of platelet-activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig. Br J Pharmacol 1987; 92: 803– 8. 141 Nijkamp FP, Braquet P, Van Heuven-Nolsen D. BN 52021 inhibits the endotoxin-induced tracheal hyperreactivity to histamine in the guinea-pig but not the increased response to histamine in the heart and coronary vessels. First International congress on the immune consequences of trauma, shock and sepsis. Munich , FRG , 1988. 142 Braquet P, Rola-Pleszczynski M. The role of PAF in immunological responses. Immunol Today 1987; 8: 345– 52. 143 Hosford D, Mencia-Huerta JM, Braquet P. The role of platelet-activating factor and structurally related alkyl phospholipids in immune cytotoxic processes. R Paoletti, ed. Advances in inflammation research, Raven Press: New York , 1989, in press. 144 Rola-Pleszczynski M, Pignol B, Pouliot C, Braquet P. Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet-activating factor (PAF-acether): reversal by a specific antagonist, BN 52021. Biochem Biophys Res Comm 1987; 142: 754– 60. 145 Pignol B, Rola-Plesczcynski M, Mencia-Huerta JM. Effect of the specific platelet-activating factor antagonists, BN 52020 and BN 52021, on interleukin 2 production by human lymphocytes. In P Braquet, ed. The ginkgolides: chemistry, biology and clinical applications. Methods and Findings, 1988; 1: 713– 18. 146 Pignol B, Henane S, Mencia-Huerta JM, Braquet P, Rola-Pleszczynski M. Platelet-activating factor (PAF-acether) inhibits interleukin 2 (IL2) production and proliferation of human lymphocytes. In: International congress of pharmacology. Sydney , 1987:abstr. 147 Rola-Pleszczynski M, Pouliot C, Pignol, Braquet P. Platelet-activating factor induces human suppressor cell activity. Fed Proc 1987:abstr. 148 Ward SG, Lewis GP, Westmick J. Platelet-activity factor receptor antagonists inhibit human T lymphocyte proliferation. In: P Braquet, ed. New trends in lipid mediator research, Vol. 1. 1988: 44– 53. 149 Barrett ML, Lewis GP, Ward S, Westwick J. Platelet-activating factor modulates interleukin-2 induced proliferation of human T-lymphoblasts. Br J Pharmacol 1986; 89: 505P. 150 Pignol B, Henane S, Sorlin B, Mencia-Huerta JM, Braquet P. Effect of long-term in vivo treatment with platelet-activating factor on interleukin 1 and interleukin 2 production by rat splenocytes. In: P Braquet, ed. New trends in lipid mediator research, Vol. 1. 1988: 38– 42. 151 Buckley RH, Becker WG. Abnormalities in the regulation of human IgE synthesis. Immunol Rev 1978; 41: 288– 314. 152 Strannegard O, Strannegard IL. T lymphocyte numbers and function in human IgE-mediated allergy. Immunol Rev 1978; 41: 149– 70. 153 Rola-Pleszczynski M, Blanchard R. Suppressor cell function in respiratory allergy. Modulation by aminophylline and isoproterenol. Int Arch Allergy Appl Immunol 1981; 64: 361– 70. 154 Rola-Pleszczynski M, Blanchard R. Abnormal suppressor cell function in atopic dermatitis. J Invest Dermatol 1981; 76: 279– 83. 155 Pignol B, Henane S, Mencia-Huerta JM, Rola-Pleszczynski M, Braquet P. Effect of PAF-acether (platelet-activating factor) and its specific antagonist, BN 52021, on interleukin 1 (IL 1) synthesis and release by rat monocytes. Prostaglandins 1987; 33: 931– 9. 156 Barrett ML, Lewis GP, Ward S, Westwick J. Platelet-activating factor induces interleukin 1 production from human adherent macrophages. Br J Pharmacol 1987; 90: 113P. 157 Vercelloti GM, Huh PW, Yin HQ, Nelson RD, Jacob HS. Enhancement of PMN-mediated endothelial damage by platelet-activating factor (PAF): PAF primes PMN responses to activating stimuli. In: 28th annual meeting of the American Society of Hematology, 1986. 158 Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987; 166: 1390– 404. 159 Hsieh KH, Lue KH. Defective monokine production and decreased responsiveness of polymorphonuclear leukocytes to recombinant interleukin 1 in asthmatic patients. J Clin Immunol 1987; 7: 203– 9. 160 Gebhardt PB, Braquet P, Bazan HBP, Bazan NG. Platelet-activating factor suppresses cell mediated immune reactions in vivo. In: P Braquet, ed. New trends in lipid mediator research, Vol. 1. Basel : Karger, 1988: 99– 107. 161 Mandi Y, Farkas G, Koltai M, Braquet P, Beladi L. The effect of BN 52021, a PAF-acether antagonist, on natural killer activity. In: P Braquet, ed. New trends in lipid mediator research, Vol. 1. Basel : Karger, 1988: 76– 84. 162 Malavasi F, Tetta C, Funaro A, Bellone G, Ferrero E, Franzone AC, Dellabona P, Rusci R, Matera L, Camussi G, Caligaris-Cappio F. Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes. Proc Natl Acad Sci USA 1986; 83: 2443– 7. 163 Nagy E, Berczi I, Wren GE, Asa SL, Kovacks K. Immunomodulation by bromocriptine. Immunopharmacology 1983; 6: 231– 43. 164 Nagy E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol 1983; 102: 351– 7. 165 Russel DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE. Prolactin receptors on human T and B lynphocytes: antagonism of prolactin binding by cyclosporin. J Immunol 1985; 134: 3027– 33. 166 Hiestand PC, Mekler P, Nordmenn R, Grieder A, Permmongkol C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action of cyclosporine. Proc Natl Acad Sci USA 1986; 83: 2599– 603. 167 Braquet P, Millerin C, Blavet N, Clostre F. Involvement of platelet-activating factor in central nervous system disorders. International congress of pharmacology. Sydney , 1987: 1498(abstr). 168 Spinnewynn B, Blavet N, Clostre F, Bazan N, Braquet P. Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in mongolian gerbils. Prostaglandins 1987; 34: 337– 49. 169 Domingo MT, Spinnewynn B, Chabner PE, Braquet P. Specific platelet-activating factor binding sites in brain. Faseb J 1988; 2: 7440(abstr). Citing Literature Volume19, Issue2March 1989Pages 125-142 ReferencesRelatedInformation